<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862096</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.258</article-id><article-id pub-id-type="other">EPP0020</article-id><article-id pub-id-type="pii">S092493382400258X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>COVID-19 Infection and Medicines in Pregnancy in Canada</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Berard</surname><given-names>A.</given-names></name><xref rid="aff0451" ref-type="aff">
<sup>1</sup></xref><xref rid="cor0119" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sheehy</surname><given-names>O.</given-names></name><xref rid="aff0451" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaul</surname><given-names>P.</given-names></name><xref rid="aff0452" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eltonsy</surname><given-names>S.</given-names></name><xref rid="aff0453" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>M.</given-names></name><xref rid="aff0454" ref-type="aff">
<sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hawken</surname><given-names>S.</given-names></name><xref rid="aff0454" ref-type="aff">
<sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bernatsky</surname><given-names>S.</given-names></name><xref rid="aff0455" ref-type="aff">
<sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pugliese</surname><given-names>M.</given-names></name><xref rid="aff0456" ref-type="aff">
<sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>O.</given-names></name><xref rid="aff0457" ref-type="aff">
<sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Savu</surname><given-names>A.</given-names></name><xref rid="aff0452" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dragan</surname><given-names>R.</given-names></name><xref rid="aff0458" ref-type="aff">
<sup>8</sup></xref></contrib></contrib-group><aff id="aff0451">
<sup>1</sup><institution>Research Centre, CHU Sainte-Justine
</institution>, <city>Montreal</city></aff><aff id="aff0452">
<sup>2</sup>Faculty of Medicine &#x00026; Dentistry, <institution>University of Alberta</institution>, <city>Edmonton</city></aff><aff id="aff0453">
<sup>3</sup>College of Pharmacy, <institution>University of Manitoba</institution>, <city>Winnipeg</city></aff><aff id="aff0454">
<sup>4</sup><institution>Ottawa Hospital Research Institute</institution>, <city>Ottawa</city></aff><aff id="aff0455">
<sup>5</sup>Department of Epidemiology, Biostatistics and Occupational Health, <institution>McGill University</institution>, <city>Montreal</city></aff><aff id="aff0456">
<sup>6</sup>Department of Epidemiology and Community Medicine, <institution>University of Ottawa</institution>, <city>Ottawa</city></aff><aff id="aff0457">
<sup>7</sup><institution>Alberta Health Services</institution>, <city>Edmonton</city></aff><aff id="aff0458">
<sup>8</sup>Manitoba Centre for Health Policy, <institution>University of Manitoba</institution>, <city>Winnipeg</city>, <country>Canada</country></aff><author-notes><corresp id="cor0119"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="233">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S106</fpage><lpage>S107</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400258Xa.pdf"/><abstract><sec id="sec0713"><title>Introduction</title><p>Although over 100 million pregnant women worldwide are at risk of infection with SARS-CoV-2, little data exists on the impact of COVID-19 and related treatments on maternal/neonatal health.</p></sec><sec id="sec0714"><title>Objectives</title><p>1) To quantify the prevalence of medication use in pregnancy to treat COVID-19; 2) To quantify and compare the risk of adverse pregnancy/neonatal outcomes in those with and without COVID-19.</p></sec><sec id="sec0715"><title>Methods</title><p>In the Canadian Mother-Child population-based cohort (CAMCCO), two key sub-cohorts were identified using prospective data collection of medical services, prescription drugs, hospitalization archives data, and COVID-19 surveillance testing program (02/28/2020-2021). The first cohort included all pregnant women with at least one completed trimester of pregnancy during the study period regardless of pregnancy status (delivery, induced/planned or spontaneous abortion); this cohort was further stratified on COVID-19 status. The second cohort included all non-pregnant women (aged 15-45) with a positive COVID-19 test. COVID-19 infection in pregnant or non-pregnant women was assessed using COVID-19 test results or ICD-10CM codeU07.1 from hospital data. COVID-19 severity was categorized based on hospital admission. Women were considered exposed to COVID-19 medications if they filled at least one prescription for a medicine included in the WHO list in the 30 days pre- or 30 days post-COVID-19 positive test/diagnosis. Considering potential confounders, association between COVID-19 during pregnancy, treated vs not, and perinatal outcomes were quantified using log-binomial regression models.</p></sec><sec id="sec0716"><title>Results</title><p>150,345 pregnant women (3,464 (2.3%) had COVID-19), and 112,073 non-pregnant women with COVID-19 diagnoses were included. Pregnant women with COVID-19 were more likely to have severe infections compared to non-pregnant women with COVID-19 (11.4% vs 1.6%, p&#x0003c; 0.001). The most frequent medications used in pregnancy to treat COVID-19 were antibacterials (13.96%), psychoanaleptics (7.35%), and medicines for obstructive airway disease (3.20%). In pregnancy COVID-19 was associated with spontaneous abortions (adjRR 1.76, 95%CI 1.3, 2.25), gestational diabetes (adjRR 1.52, 95%CI 1.18, 1.97), prematurity (adjRR 1.30, 95%CI 1.01, 1.67), NICU admissions (adjRR 1.32, 95%CI 1.10, 1.59); COVID-19 severity was increasing these risks but COVID-19 treatment with study medications reduced all risks.</p></sec><sec id="sec0717"><title>Conclusions</title><p>Severity of COVID-19 was greater in pregnancy. Antibacterials, psychoanaleptics, and medicines for obstructive airway disease were the most used overall. Severe COVID-19 in pregnancy was associated with higher risks of adverse maternal, and neonatal outcomes.</p></sec><sec id="sec0718"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>